SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
Live event scheduled for Friday, February 24th at 11:00 am Eastern TimeIRVINE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- AEON...
PRL-02 continues to demonstrate strong safety along with dose-dependent reductions in testosterone and PSA Recently issued U.S. patent expands PRL-02...
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...
AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader...
TORONTO and TEL AVIV, Israel, Feb. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a...
Topline trial results expected mid-March 2023NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical...
Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase...
MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive...
- Q-Code assigned to CIMERLI® for Medicare claims processing effective for dates of service on and after April 1, 2023...
-- Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward...
SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical...
Based on Type C guidance requested and received from the U.S. Food and Drug Administration (FDA), Akari announces it is...
Topline results including safety and proof-of-mechanism data expected in third quarter of 2023CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023...
If Approved Later This Year, Nyxol Could be the Only Commercially Available Eye Drop for Reversal of DilationFARMINGTON HILLS, Mich.,...
-- Board and Management Team to Answer Shareholder Questions -- DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE)...
MINNEAPOLIS, Feb. 13, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an emerging biomedical device company...
PALO ALTO, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...